Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹397.3 Cr | ₹441.4 Cr | ₹424 Cr | ₹858.4 Cr |
| Net Profit | ₹9.3 Cr | ₹14.3 Cr | ₹14.7 Cr | ₹38.4 Cr |
| EPS | — | ₹0.57 | ₹0.59 | ₹0.89 |
| Operating Profit | ₹42.8 Cr | ₹54.8 Cr | ₹56.1 Cr | ₹148.4 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 08 Sept 2021 | Dividend - Rs 0.50 Per Share | DIVIDEND |
| 21 Aug 2019 | Annual General Meeting/Dividend - Rs 0.20 Per Share | AGM |
| 06 Apr 2018 | Scheme Of Arrangement | MERGER_ACQUISITION |
| 20 Nov 2017 | Interim Dividend - Re 0.20 Per Share | INTERIM_DIVIDEND |
| 15 Sept 2016 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for VIYASH
View All
Trading guide: Check key Nifty levels to watch; two stocks to buy today
Vinay Rajani of HDFC Securities suggests Nifty trading strategy and suggests buying Bank of Maharashtra, and Viyash Scientific; here's why
Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 crore
Viyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion animal health business. BioForLife offers a strong presence in the Italian pet care market. The acquisition is expected to finalize in the second quarter of FY 2026-27.
Viyash Scientific to acquire Milan-based pet care company BioForLife
Viyash Scientific (Viyash), through its wholly owned subsidiary Alivira Animal Health (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of Rs 188 crore is expected to close in Q2 FY27.